12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ramucirumab: Interim Phase II data

Interim data from an open-label, international Phase II trial in 140 evaluable chemotherapy-naïve patients with advanced non-squamous NSCLC showed that 10 mg/kg ramucirumab plus Alimta pemetrexed and carboplatin or cisplatin every 3 weeks led to a median PFS of 6.3 months vs. 4.3 months for Alimta plus carboplatin or cisplatin. The DCR...

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >